Press releases
- IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- IDEAYA Announces Pricing of Public Offering
- IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
- IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
- IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
- IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
- IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
More ▼
Key statistics
On Tuesday, IDEAYA Biosciences Inc (30J:MUN) closed at 39.00, -11.76% below its 52-week high of 44.20, set on Feb 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.00 |
---|---|
High | 39.00 |
Low | 39.00 |
Bid | -- |
Offer | -- |
Previous close | 39.00 |
Average volume | 30.00 |
---|---|
Shares outstanding | 83.12m |
Free float | 82.28m |
P/E (TTM) | -- |
Market cap | 3.55bn USD |
EPS (TTM) | -2.00 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 07:04 BST.
More ▼